ACE and Insulin resistance: In the Study of Trandolapril/verapamil SR [sustained release] and Insulin Resistance (STAR),18 200 obese patients were randomly assigned to receive either an angiotensin-converting enzyme (ACE) inhibitor plus a calcium-channel blocker or an angiotensin-receptor blocker (ARB) plus a low-dose thiazide diuretic.